BioPharmSignal logoBioPharmSignal

Biotech News

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

Disc Medicine (IRON)Disc MedicineEarnings

Pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria (EPP) successfully met all primary and secondary endpoints Bitopertin NDA resubmission planned by end of 2026, with an FDA decision for potential approval in EPP anticipated by mid-2027 Feedback from the upcoming end of

Related news

IRONDisc Medicine2026-07-30 12:30 EST

Disc Medicine Reports Second Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-05-05 12:30 EST

Disc Medicine Reports First Quarter 2026 Financial Results and Provides Business Update

SNDXSyndax Pharmaceuticals2026-11-02 21:01 EST

Syndax Reports Third Quarter 2026 Financial Results and Provides Business Update

RIGLRigel Pharmaceuticals2026-10-29 12:05 EST

Rigel Announces Conference Call and Webcast to Report Third Quarter 2026 Financial Results

SNDXSyndax Pharmaceuticals2026-10-26 11:00 EST

Syndax to Announce Third Quarter 2026 Financial Results and Host Conference Call and Webcast on November 2, 2026

GERNGeron2026-10-21 12:00 EST

Geron Plans to Announce Third Quarter 2026 Financial Results on November 4, 2026

KPTIKaryopharm Therapeutics2026-08-13 11:30 EST

Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission

RCKTRocket Pharmaceuticals2026-08-10 20:00 EST

Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress

ZNTLZentalis2026-08-06 20:05 EST

Zentalis Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Updates

ZNTLZentalis2026-05-12 20:05 EST

Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress

View all latest news

Disc Medicine

Hematology Drug Development Disc Medicine develops therapies for serious hematologic diseases by targeting pathways involved in heme biosynthesis and iron regulation. Its portfolio addresses both rare red-blood-cell disorders and anemia associated with chronic disease. Bitopertin in EPP Bitopertin is being evaluated in the Phase 3 APOLLO...

Recent company news

IRONDisc Medicine2026-11-05 13:30 EST

Disc Medicine Reports Third Quarter 2026 Financial Results and Provides Business Update

IRONDisc Medicine2026-11-04 14:05 EST

Disc Medicine Announces Multiple Presentations Across Portfolio at the 68th American Society of Hematology (ASH) Annual Meeting

IRONDisc Medicine2026-11-02 13:30 EST

Disc Medicine to Participate in Upcoming Investor Conferences

IRONDisc Medicine2026-10-21 00:52 EST

Disc Medicine Announces Pricing of $450 Million Upsized Public Offering of Common Stock

IRONDisc Medicine2026-10-19 20:01 EST

Disc Medicine Announces Proposed $350 Million Public Offering of Common Stock and Pre-Funded Warrants

Stock data

Close
78.47 USD
Market cap
2.6B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States